Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Biotech
Axsome adds AZ asset through Avenue subsidiary acquisition
Axsome is after BAER-101, a phase 2 oral GABA receptor modulator that Avenue's Baergic Bio originally licensed from AstraZeneca in December 2019.
Darren Incorvaia
Nov 6, 2025 10:50am
Novo Nordisk CEO 'feels' Danish pharma will bag Metsera
Nov 5, 2025 4:20am
Qiagen CEO to step down as company snaps up Parse Biosciences
Nov 4, 2025 2:22pm
Novo, Pfizer bidding war for Metsera heats up with larger offers
Nov 4, 2025 10:18am
Pfizer sues Metsera over Novo offer, but biotech stands firm
Nov 3, 2025 4:04am
Thermo Fisher to buy Clario in $9B deal
Oct 31, 2025 12:41pm
